ArticleJournal of bone oncology2021

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer.

Mark Clemons et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.